• Song Xia, Zhong Liu, Huifang Yan, Kun Chang, Yuguang Sun, Jingmin Wang, and Wenbin Shen.
• Department of Lymphatic Surgery, Beijing Shijitan Hospital, Capital Medical University.
• Medicine (Baltimore). 2021 Jun 18; 100 (24): e26307.

Introduction22q13.3 deletion syndrome is a well-known syndrome characterized by typical clinical findings including neonatal hypotonia, absent or severely delayed speech, intellectual disability, and other various features, and detection of a heterozygous deletion of chromosome 22q13.3 with the involvement of at least part of SHANK3. It is reported that 10% to 29% of patients with 22q13.3 deletion syndrome present lymphedema. Protein-losing enteropathy (PLE) has never been reported in 22q13.3 deletion syndrome.Patient ConcernsThe patient presented to our institution for refractory hypoalbuminemia and chronic lymphedema in both legs.DiagnosisThe patient manifested intellectual disability, absent speech, tooth grinding, dysmorphic face, and abnormal hands and toenails. Copy-number variation sequencing confirmed the maternal deletion in 22q13.31-q13.33 (chr22:46285592-51244566, hg19). The patient was genetically diagnosed with 22q13.3 deletion syndrome.InterventionsLow-fat diets and medium-chain triglycerides supplements were prescribed. The patient was recommended to wear compression garments and elevate legs.OutcomesThe symptom of diarrhea was resolved, but hypoalbuminemia persisted. Lower extremities lymphedema was gradually becoming severe.ConclusionsPrimary lymphedema and PLE can occur simultaneously in a patient with 22q13.3 deletion syndrome. The 2 phenotypes could share the same genetic etiology of congenital lymphatic abnormalities. CELSR1 deletion may play a role in lymphatic dysplasia. The case also provides additional proof of the pathogenic effect of CELSR1 on hereditary lymphedema.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

21 keywords...

hide…